Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/5312
Email LibraryRMU.DOH@nt.gov.au to ask for this document in a different format
Title: Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Authors: Tsai, Danny
Stewart, Penelope
Goud, Rajendra
Gourley, Stephen
Hewagama, Saliya
Krishnaswamy, Sushena
Wallis, Steven C
Lipman, Jeffrey
Roberts, Jason A
Citation: International journal of antimicrobial agents 2016-11; 48(5): 542-546
Abstract: Currently there are no pharmacokinetic (PK) data to guide antibiotic dosing in critically ill Australian Indigenous patients with severe sepsis. This study aimed to determine whether the population pharmacokinetics of meropenem were different between critically ill Australian Indigenous and critically ill Caucasian patients. Serial plasma and urine samples as well as clinical and demographic data were collected over two dosing intervals from critically ill Australian Indigenous patients. Plasma meropenem concentrations were assayed by validated chromatography. Concentration-time data were analysed with data from a previous PK study in critically ill Caucasian patients using Pmetrics. The population PK model was subsequently used for Monte Carlo dosing simulations to describe optimal doses for these patients. Six Indigenous and five Caucasian subjects were included. A two-compartment model described the data adequately, with meropenem clearance and volume of distribution of the central compartment described by creatinine clearance (CLCr) and patient weight, respectively. Patient ethnicity was not supported as a covariate in the final model. Significant differences were observed for meropenem clearance between the Indigenous and Caucasian groups [median 11.0 (range 3.0-14.1) L/h vs. 17.4 (4.3-30.3) L/h, respectively; P <0.01]. Standard dosing regimens (1 g intravenous every 8 h as a 30-min infusion) consistently achieved target exposures at the minimum inhibitory concentration breakpoint in the absence of augmented renal clearance. No significant interethnic differences in meropenem pharmacokinetics between the Indigenous and Caucasian groups were detected and CLCr was found to be the strongest determinant of appropriate dosing regimens.
Click to open PubMed article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/27771187
Click to open Pubmed Article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/27771187
Journal title: International journal of antimicrobial agents
Publication Date: 2016-11
Type: Journal Article
Observational Study
URI: https://hdl.handle.net/10137/5312
DOI: 10.1016/j.ijantimicag.2016.08.015
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.